18F-SMBT-1 PET studies of beta-amyloid-positive Alzheimer’s disease patients (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

18F-SMBT-1 PET studies of beta-amyloid-positive Alzheimer’s disease patients

Caption

18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.

Credit

Image created by Victor Villemagne, MD, Professor of Psychiatry at the University of Pittsburgh.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.